Cereno Scientific AB Series B
Research Cereno Scientific AB Series B (CRNO-B) on Bullrun: market cap SEK 1.45B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCRNO-B
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Market capSEK 1.45B
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 28.60M
- Free cash flow-SEK 58.68M
Valuation Snapshot
latest market cap is SEK 1.45B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 117.67M | -SEK 156.34M | n/a | -0.39 | SEK 74.64M | SEK 125.00M | SEK 252.47M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 1.45B | n/a | n/a | n/a |
About Cereno Scientific AB Series B
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cereno Scientific AB Series B's market cap?
Cereno Scientific AB Series B's market capitalization is SEK 1.45B.
What does Cereno Scientific AB Series B do?
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. The company's lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator for pathological vascular remodeling, fibrotic tissue remodeling, inflammatory processes, pulmonary arterial pressure, thrombotic mechanisms.